An Open-label Phase 1/2A Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients With Metastatic Castration-resistant Prostate Cancer
Phase of Trial: Phase I/II
Latest Information Update: 07 Nov 2017
At a glance
- Drugs TRC 253 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors TRACON Pharmaceuticals
- 07 Nov 2017 According to a TRACON Pharmaceuticals media release, dose escalation portion is expected to complete in the 1H 2018.
- 17 Oct 2017 Planned End Date changed from 1 Sep 2018 to 1 Oct 2018.
- 17 Oct 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.